| 1.63 0.02 (1.24%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.07 | 1-year : | 2.27 |
| Resists | First : | 1.77 | Second : | 1.95 |
| Pivot price | 1.73 |
|||
| Supports | First : | 1.49 | Second : | 1.23 |
| MAs | MA(5) : | 1.62 |
MA(20) : | 1.71  |
| MA(100) : | 1.47 |
MA(250) : | 1.25 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.6 |
D(3) : | 12.1 |
| RSI | RSI(14): 45.9 |
|||
| 52-week | High : | 1.95 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LXRX ] has closed above bottom band by 23.6%. Bollinger Bands are 4.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.66 - 1.66 | 1.66 - 1.67 |
| Low: | 1.56 - 1.56 | 1.56 - 1.57 |
| Close: | 1.62 - 1.63 | 1.63 - 1.64 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Sat, 02 May 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above 200-Day Moving Average - Here's What Happened - MarketBeat
Sat, 02 May 2026
Lexicon Pharmaceuticals (LXRX) to Release Earnings on Thursday - MarketBeat
Fri, 01 May 2026
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851 - Insider Monkey
Fri, 01 May 2026
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851 - Yahoo Finance
Thu, 30 Apr 2026
[8-K] LEXICON PHARMACEUTICALS, INC. Reports Material Event - Stock Titan
Mon, 27 Apr 2026
Lexicon Pharmaceuticals (LXRX) price target increased by 15.07% to 3.43 - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 424 (M) |
| Shares Float | 418 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 68.5 (%) |
| Shares Short | 22,930 (K) |
| Shares Short P.Month | 23,140 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -101.1 % |
| Operating Margin | -269.1 % |
| Return on Assets (ttm) | -12.7 % |
| Return on Equity (ttm) | -39.8 % |
| Qtrly Rev. Growth | -79.4 % |
| Gross Profit (p.s.) | 0.1 |
| Sales Per Share | 0.11 |
| EBITDA (p.s.) | -0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -68 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -11.65 |
| PEG Ratio | -13.8 |
| Price to Book value | 5.43 |
| Price to Sales | 13.86 |
| Price to Cash Flow | -10.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|